筋萎縮性側索硬化症のモデルにおけるシナプス機能のリアルタイム蛍光測定

Executive Industry Relevance

Real-time fluorescent measurement of synaptic functions provides a rapid, quantitative readout of presynaptic activity in neuronal models, enabling early assessment of compound effects on neurotransmission. This approach supports target validation and mechanistic de-risking in neurodegenerative disease programs by linking molecular perturbations to functional synaptic outputs. The multiplexable design allows integration with overexpression of disease-associated proteins, facilitating phenotypic screening and translational biomarker alignment in ALS and related models.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates therapeutic hypotheses by measuring depolarization-mediated synaptic vesicle exocytosis and calcium influx as functional readouts of neuronal health.
• Operational Value: Enables rapid screening of compounds that may restore synaptic function in disease models, reducing reliance on slower electrophysiology.
• Predictive Value: Supports portfolio triage by quantifying synaptic rescue in FUS-ALS and C9ORF72-ALS models using primary rodent cortical and motor neurons.

Screening & Assay Development

• Assay Readiness: Generates normalized fluorescence readouts of styryl dye loss and GCaMP6m gain, providing unambiguous, quantifiable metrics of vesicle release and calcium dynamics.
• Reproducibility: Requires consistent excitation power, exposure time, detector gain, and frame rate across samples to ensure reliable longitudinal comparisons.
• Scalability: Compatible with high-content imaging platforms and perfusion systems, enabling time-lapse acquisition over 3–5 minute basal and 5 minute stimulation phases.

Translational & Preclinical Research

• Disease Relevance: Directly models synaptic dysfunction in FUS-ALS and C9ORF72-ALS, capturing early pathophysiological changes preceding neurodegeneration.
• Translational Continuity: Bridges discovery and preclinical validation by providing functional readouts that correlate with neuronal communication deficits in motor and cognitive domains.
• Risk-Adjusted Decisions: Enables evaluation of whether disease-associated proteins or RNAs impair synaptic transmission, informing target confidence and lead identification.

Pipeline & Workflow Integration

The method fits within the discovery continuum from target validation through lead identification to preclinical efficacy testing, particularly for neurodegenerative disease programs where synaptic dysfunction is an early biomarker.

• Discovery Biology: Supports hypothesis testing by linking genetic or pharmacological manipulations to changes in synaptic vesicle recycling and presynaptic calcium flux.
• Screening: Delivers assay-ready, quantitative outputs (fluorescence intensity over time) that enable comparison of compound effects across conditions.
• Analytics: Provides normalized fluorescence measurements that allow teams to assess synaptic function rescue or impairment relative to baselines.
• Translational Research: Aligns with biomarker strategies by modeling synaptic deficits in human-relevant ALS genotypes using primary and iPSC-derived neurons.
• Enterprise Reuse: Establishes a reusable imaging platform for longitudinal assessment of synaptic health across multiple projects and therapeutic modalities.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence by reducing mechanistic ambiguity between genetic insults and functional synaptic outcomes.
• Operational Value: Standardizes synaptic function assessment via reproducible live-imaging protocols with built-in baseline and stimulation phases.
• Strategic Value: Improves go/no-go decisions by offering early, functional evidence of target engagement in neuronal models.
• Portfolio Impact: Supports risk-adjusted prioritization of compounds that demonstrate synaptic rescue in ALS-relevant systems.

Implementation Considerations

• Requires expertise in confocal microscopy, live-cell imaging, and fluorescent dye handling (styryl dye and GCaMP6m).
• Dependent on stable perfusion systems and image acquisition software with perfect focus to minimize drift during time-lapse acquisition.
• Necessitates standardization of staining, incubation, and perfusion protocols across laboratories to ensure cross-site reproducibility.
• Adaptation to iPSC-derived neurons requires optimization of transfection efficiency and maturation timing while maintaining consistent KCl stimulation parameters.
• Practical limitation: Extended culturing post-perfusion is discouraged due to air exposure, limiting downstream assays to fixed endpoints like immunostaining or molecular extraction.

Biopharma FAQs